Biotech

All Articles

AstraZeneca messages data on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has discussed a very early consider the performance of its own in-house antibody-drug c...

iTeos- GSK's TIGIT star reveals meaningful improvement

.After revealing a period 3 launch based on favorable midstage results, iTeos and also GSK are actua...

More collective FDA may accelerate uncommon health condition R&ampD: file

.The FDA should be actually even more open and collective to discharge a rise in commendations of un...

Zenas, MBX, Bicara head to Nasdaq in warm day for biotech IPOs

.It's an unusually occupied Friday for biotech IPOs, with Zenas BioPharma, MBX as well as Bicara Reh...

Atea's COVID antiviral fails to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has failed another COVID-19 trial, yet the biotech still stores out...

Neurocrine's bid to save schizophrenia prospect fails

.Neurocrine Biosciences' schizophrenia course pivot has actually stopped working. The biotech was ac...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has actually created an overdue entrance to the radioligand gathering, paying 100 million eu...

F 2G raises $100M for second try to receive new antifungal to market

.After F2G's first effort to receive a new course of antifungal to market was actually derailed due ...

Moderna targets $1.1 B in R&ampD spending slices, drops 5 systems amidst productivity pressures

.Moderna has vowed to reduce R&ampD costs through $1.1 billion by 2027. The decision to shrink the b...

Sanofi's $80M bet on Key dystrophy drug finishes in stage 3 crash

.Just 4 months after Sanofi wager $80 thousand in upfront cash money on Key Therapies' losmapimod, t...